$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000162828017008044 Filed on August 03, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2016 Q2
Revenue	$6.892M	$1.039M	$309.0K
YoY Change	790.44%	236.25%	-91.02%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.660M	$4.600M	$23.77M
YoY Change	-1.61%	-80.65%	210.31%
% of Gross Profit
Research & Development	$15.54M	$15.45M	$15.22M
YoY Change	-1.28%	1.51%	57.02%
% of Gross Profit
Depreciation & Amortization	$593.0K	$480.0K	$252.0K
YoY Change	103.78%	90.48%	71.43%
% of Gross Profit
Operating Expenses	$19.79M	$20.52M	$195.6M
YoY Change	0.2%	-89.5%	994.94%
Operating Profit	-$12.90M	-$19.49M	-$195.2M
YoY Change	-32.03%	-90.02%	1254.01%
Interest Expense	$76.00K	$68.00K	$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	$1.297M	$1.230M	$384.0K
YoY Change	-309.19%	220.31%	-182.4%
Pretax Income	-$11.60M	-$18.26M	-$194.9M
YoY Change	-40.8%	-90.63%	1209.04%
Income Tax	$0.00	$0.00	-$64.86M
% Of Pretax Income
Net Earnings	-$11.60M	-$18.26M	-$130.0M
YoY Change	-40.8%	-85.96%	773.3%
Net Earnings / Revenue	-168.31%	-1756.98%	-42071.2%
Basic Earnings Per Share		-$0.33
Diluted Earnings Per Share	-$211.4K	-$0.33	-$2.466M
COMMON SHARES
Basic Shares Outstanding	55.03M shares	54.65M shares	54.63M shares
Diluted Shares Outstanding		54.65M shares

Balance Sheet

Concept	2017 Q3	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$88.20M	$103.0M	$165.3M
YoY Change	-41.08%	-37.69%	-20.22%
Cash & Equivalents	$15.23M	$24.21M	$42.97M
Short-Term Investments	$73.00M	$78.80M	$122.3M
Other Short-Term Assets	$1.500M	$1.600M	$2.000M
YoY Change	0.0%	-20.0%	11.11%
Inventory
Prepaid Expenses
Receivables	$846.0K	$1.042M	$456.0K
Other Receivables	$100.0K	$100.0K	$100.0K
Total Short-Term Assets	$90.81M	$105.9M	$168.1M
YoY Change	-40.18%	-36.98%	-22.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.62M	$12.74M	$3.944M
YoY Change	208.91%	223.1%	93.71%
Goodwill	$24.36M	$24.36M	$162.5M
YoY Change	-85.01%	-85.01%	4.14%
Intangibles	$99.45M	$99.45M	$196.3M
YoY Change	-49.34%	-49.34%	-49.66%
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets	$12.60M	$12.60M
YoY Change
Total Long-Term Assets	$149.0M	$149.2M	$362.8M
YoY Change	-58.94%	-58.89%	-35.0%
TOTAL ASSETS
Total Short-Term Assets	$90.81M	$105.9M	$168.1M
Total Long-Term Assets	$149.0M	$149.2M	$362.8M
Total Assets	$239.8M	$255.1M	$530.9M
YoY Change	-53.4%	-51.95%	-31.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.300M	$3.400M	$1.700M
YoY Change	9.52%	100.0%	-39.29%
Accrued Expenses	$4.100M	$4.100M	$5.700M
YoY Change	-14.58%	-28.07%	50.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.235M	$11.88M	$10.08M
YoY Change	-1.87%	17.82%	-37.49%
LONG-TERM LIABILITIES
Long-Term Debt	$12.00M	$12.00M	$0.00
YoY Change
Other Long-Term Liabilities	$11.00M	$14.10M	$8.000M
YoY Change	32.53%	76.25%	-39.39%
Total Long-Term Liabilities	$23.00M	$26.10M	$8.000M
YoY Change	177.11%	226.25%	-39.39%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.235M	$11.88M	$10.08M
Total Long-Term Liabilities	$23.00M	$26.10M	$8.000M
Total Liabilities	$72.45M	$79.29M	$99.54M
YoY Change	-26.15%	-20.34%	-46.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$699.6M	-$688.0M	-$412.9M
YoY Change	61.78%	66.65%	77.39%
Common Stock	$876.0M	$873.8M	$861.1M
YoY Change	1.35%	1.47%	4.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$167.4M	$175.8M	$431.3M
YoY Change
Total Liabilities & Shareholders Equity	$239.8M	$255.1M	$530.9M
YoY Change	-53.4%	-51.95%	-31.4%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$11.60M	-$18.26M	-$130.0M
YoY Change	-40.8%	-85.96%	773.3%
Depreciation, Depletion And Amortization	$593.0K	$480.0K	$252.0K
YoY Change	103.78%	90.48%	71.43%
Cash From Operating Activities	-$15.68M	-$5.078M	-$16.80M
YoY Change	6.58%	-69.78%	0.8%
INVESTING ACTIVITIES
Capital Expenditures	$538.0K	$3.121M	$954.0K
YoY Change	220.24%	227.15%	149.09%
Acquisitions
YoY Change
Other Investing Activities	$5.840M	$1.730M	-$84.44M
YoY Change	-922.54%	-102.05%	748.64%
Cash From Investing Activities	$5.305M	-$1.390M	-$85.39M
YoY Change	-702.84%	-98.37%	726.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$61.00K	$4.000K	$446.0K
YoY Change	-19.74%	-99.1%	-53.54%
NET CHANGE
Cash From Operating Activities	-$15.68M	-$5.078M	-$16.80M
Cash From Investing Activities	$5.305M	-$1.390M	-$85.39M
Cash From Financing Activities	$61.00K	$4.000K	$446.0K
Net Change In Cash	-$8.987M	-$6.464M	-$101.8M
YoY Change	-42.08%	-93.65%	290.78%
FREE CASH FLOW
Cash From Operating Activities	-$15.68M	-$5.078M	-$16.80M
Capital Expenditures	$538.0K	$3.121M	$954.0K
Free Cash Flow	-$16.22M	-$8.199M	-$17.76M
YoY Change	8.99%	-53.83%	4.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	2178000	USD
CY2017Q2	abus	Accrued Payroll Current AccruedPayrollCurrent	214000	USD
CY2016Q4	abus	Accrued Research And Development AccruedResearchAndDevelopment	3131000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	496000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Depreciation Depreciation	469000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000	USD
CY2017Q2	abus	Accrued Research And Development AccruedResearchAndDevelopment	3215000	USD
	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	-315000	USD
CY2017Q1	abus	Classof Warrantor Rights Expired ClassofWarrantorRightsExpired	22000	shares
	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	2853000	USD
	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	3702000	CAD
CY2016Q4	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	553000	USD
CY2017Q2	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	983000	USD
CY2016Q4	abus	Employee Stock Options Liability Classified Outstanding Fair Value Disclosure EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure	553000	USD
CY2017Q2	abus	Employee Stock Options Liability Classified Outstanding Fair Value Disclosure EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure	983000	USD
	abus	Fair Value Of Warrants Exercised In The Period FairValueOfWarrantsExercisedInThePeriod	246000	USD
	abus	Fair Value Of Warrants Exercised In The Period FairValueOfWarrantsExercisedInThePeriod	129000	USD
CY2016Q2	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	252000	USD
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	496000	USD
CY2017Q2	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	-110000	USD
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	949000	USD
	abus	Increase Decrease In Value Of Warrants IncreaseDecreaseInValueOfWarrants	-329000	USD
	abus	Increase Decrease In Value Of Warrants IncreaseDecreaseInValueOfWarrants	22000	USD
	abus	Maximum Contribution For Product MaximumContributionForProduct	9323000	CAD
	abus	Maximum Contribution For Product MaximumContributionForProduct	7179000	USD
CY2006Q2	abus	Number Of Chemotherapy Products With Worldwide Licenses NumberOfChemotherapyProductsWithWorldwideLicenses	3	chemotherapy_products
CY2016Q2	abus	Option Exercised Contractual Option Revenue Amount OptionExercisedContractualOptionRevenueAmount	0	USD
	abus	Option Exercised Contractual Option Revenue Amount OptionExercisedContractualOptionRevenueAmount	1000000	USD
CY2017Q2	abus	Option Exercised Contractual Option Revenue Amount OptionExercisedContractualOptionRevenueAmount	0	USD
	abus	Option Exercised Contractual Option Revenue Amount OptionExercisedContractualOptionRevenueAmount	0	USD
	abus	Percent Of Costs Funded By Tpc PercentOfCostsFundedByTPC	0.27
	abus	Royalty Guarantees Commitments Percentage RoyaltyGuaranteesCommitmentsPercentage	0.025
	abus	Warrants Exercised WarrantsExercised	170500	shares
	abus	Warrants Exercised WarrantsExercised	179000	shares
CY2017Q2	abus	Wholly Owned Subsidiaries Includedin Financial Statements WhollyOwnedSubsidiariesIncludedinFinancialStatements	2	subsidiary
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55026995	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Arbutus Biopharma Corp
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9910000	USD
CY2017Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8274000	USD
CY2016Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3215000	USD
CY2017Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3368000	USD
CY2016Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	273000	USD
CY2017Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	1042000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	273000	USD
	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	108000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	498000	USD
CY2017Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1042000	USD
CY2016Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	252000	USD
CY2017Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	305000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10738000	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11541000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-49782000	USD
CY2017Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-49782000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	36543000	USD
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	39758000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9492000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5488162	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5848138	shares
CY2016Q4	us-gaap	Assets Assets	275919000	USD
CY2017Q2	us-gaap	Assets Assets	255075000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	132564000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	105922000	USD
CY2016Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	143160000	USD
CY2017Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	115610000	USD
CY2017Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-110000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	949000	USD
CY2015Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7497000	USD
CY2016Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7993000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	9065000	USD
CY2017Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	10014000	USD
CY2016Q2	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2017Q2	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	72000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	72000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	166779000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	144772000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42970000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23413000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29851000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24212000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	23413000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	24212000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-101802000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-123809000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5639000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	799000	USD
CY2016Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2017Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54841494	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55026983	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54841494	shares
	us-gaap	Depreciation Depreciation	814000	USD
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55026983	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	867393000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	15000	USD
CY2017Q2	us-gaap	Depreciation Depreciation	480000	USD
CY2016Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-64864000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-64864000	USD
CY2017Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2016Q4	us-gaap	Deferred Revenue DeferredRevenue	15000	USD
CY2017Q2	us-gaap	Deferred Revenue DeferredRevenue	6754000	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	873841000	USD
CY2016Q2	us-gaap	Contracts Revenue ContractsRevenue	32000	USD
	us-gaap	Contracts Revenue ContractsRevenue	139000	USD
CY2017Q2	us-gaap	Contracts Revenue ContractsRevenue	318000	USD
	us-gaap	Contracts Revenue ContractsRevenue	336000	USD
CY2017Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2624000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2017Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4130000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	41263000	USD
CY2017Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	41263000	USD
CY2016Q2	us-gaap	Depreciation Depreciation	252000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.47
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.80
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.68
CY2016Q2	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-51000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2956000	USD
CY2017Q2	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	825000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	1248000	USD
CY2016Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	168000	USD
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	329000	USD
CY2017Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	USD
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-22000	USD
CY2016Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	33000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2975000	USD
CY2017Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	798000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1225000	USD
CY2016Q2	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-51000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	2956000	USD
CY2017Q2	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	824000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1250000	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23766000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30985000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4599000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8927000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	24364000	USD
CY2017Q2	us-gaap	Goodwill Goodwill	24364000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	156324000	USD
CY2016Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	350000	USD
CY2017Q2	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	825000	USD
CY2016Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	293000	USD
CY2017Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	160000	USD
CY2016Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	42000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1074000	USD
CY2017Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2205000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1708000	USD
CY2016Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	116000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-552000	USD
CY2016Q2	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	156324000	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	156324000	USD
CY2017Q2	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-194864000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-210738000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-18255000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-36882000	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-64864000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-64864000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6691000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	914000	USD
CY2016Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-213000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-370000	USD
CY2017Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-653000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	6739000	USD
CY2016Q2	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-98000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-98000	USD
CY2017Q2	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-294000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-279000	USD
CY2016Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	573000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	847000	USD
CY2017Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	273000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	99445000	USD
CY2017Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	99445000	USD
CY2016Q2	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	0	USD
CY2017Q2	us-gaap	Interest Expense InterestExpense	68000	USD
	us-gaap	Interest Expense InterestExpense	110000	USD
CY2016Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	435000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	679000	USD
CY2017Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	390000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	758000	USD
CY2016Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	107146000	USD
CY2017Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	78797000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	72914000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	79289000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	275919000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	255075000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10585000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11881000	USD
CY2016Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	9725000	USD
CY2017Q2	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	10997000	USD
CY2016Q2	us-gaap	Licenses Revenue LicensesRevenue	277000	USD
	us-gaap	Licenses Revenue LicensesRevenue	773000	USD
CY2017Q2	us-gaap	Licenses Revenue LicensesRevenue	721000	USD
	us-gaap	Licenses Revenue LicensesRevenue	938000	USD
CY2016Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	12001000	USD
CY2017Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	12001000	USD
CY2016Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	446000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	561000	USD
CY2017Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	358000	USD
CY2016Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-85393000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-98975000	USD
CY2017Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1390000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	21810000	USD
CY2016Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16804000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28351000	USD
CY2017Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5078000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22617000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-130000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-145874000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-18255000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-36882000	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	384000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4487000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1230000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	902000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	195557000	USD
	us-gaap	Operating Expenses OperatingExpenses	216137000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	20524000	USD
	us-gaap	Operating Expenses OperatingExpenses	39058000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-195248000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-215225000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-19485000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-37784000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	538000	USD
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	347000	USD
CY2016Q2	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	84439000	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	97745000	USD
CY2017Q2	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-1731000	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-28349000	USD
CY2016Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	954000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1230000	USD
CY2017Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3121000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6539000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1311000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1583000	USD
CY2016Q2	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	0	USD
	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	0	USD
CY2017Q2	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	108000	USD
CY2016Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2016Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	116000	USD
CY2017Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5000	USD
CY2016Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	445000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	445000	USD
CY2017Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	353000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17683000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24284000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6945000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12743000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15215000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28359000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15445000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29317000	USD
CY2016Q4	us-gaap	Restricted Investments At Fair Value RestrictedInvestmentsAtFairValue	12601000	USD
CY2017Q2	us-gaap	Restricted Investments At Fair Value RestrictedInvestmentsAtFairValue	12601000	USD
CY2016Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	12601000	USD
CY2017Q2	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	12601000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-651149000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-688031000	USD
CY2016Q2	us-gaap	Revenues Revenues	309000	USD
	us-gaap	Revenues Revenues	912000	USD
CY2017Q2	us-gaap	Revenues Revenues	1039000	USD
	us-gaap	Revenues Revenues	1274000	USD
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	107146000	USD
CY2017Q2	us-gaap	Short Term Investments ShortTermInvestments	78797000	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	481000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	203005000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	175786000	USD
CY2016Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	128000	USD
CY2017Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	128000	USD
CY2016Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	107000	USD
CY2017Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2015Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	883000	USD
CY2016Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	308000	USD
CY2016Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	107000	USD
CY2017Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	0	USD
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52716059	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52052165	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54647944	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54478221	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of business and future operations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (the “Company” or “Arbutus”) is a biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (“HBV”). The Company's portfolio of assets includes a broad pipeline of drug candidates to develop a cure for HBV and leverages the Company’s expertise in Lipid Nanoparticle ("LNP") technology.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The continuation of the research and development activities and the commercialization of its products are dependent on the Company’s ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of future research and development programs or the Company’s ability to continue to fund these programs in the future.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-17-008044-index-headers.html	Edgar Link	pending
0001628280-17-008044-index.html	Edgar Link	pending
0001628280-17-008044.txt	Edgar Link	pending
0001628280-17-008044-xbrl.zip	Edgar Link	pending
abus-20170630.xml	Edgar Link	completed
abus-20170630.xsd	Edgar Link	pending
abus-20170630_cal.xml	Edgar Link	unprocessable
abus-20170630_def.xml	Edgar Link	unprocessable
abus-20170630_lab.xml	Edgar Link	unprocessable
abus-20170630_pre.xml	Edgar Link	unprocessable
arbutusq22017.htm	Edgar Link	pending
exhibit311q22017.htm	Edgar Link	pending
exhibit312q22017.htm	Edgar Link	pending
exhibit321q22017.htm	Edgar Link	pending
exhibit322q22017.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pipeline20170721.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2017 Q3 Form 10-Q Financial Statement

#000162828017008044 Filed on August 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2017 Q3 Form 10-Q Financial Statement

#000162828017008044 Filed on August 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus